Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

NCT00515411 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

111

Enrollment

OTHER

Sponsor class

Conditions

Gastroesophageal Junction Adenocarcinoma
Gastric Cancer

Interventions

DRUG: Docetaxel, Leucovorin, Fluorouracil, Cisplatin
DRUG: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
DRUG: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]